{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:16:06Z","timestamp":1779387366132,"version":"3.53.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"name":"National Institute of Health","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"The Adam Spector Foundation"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Combined modality therapy (CMT; chemotherapy with consolidative radiation) has led to excellent long-term outcomes in patients with early-stage Hodgkin lymphoma. However, despite high cure rates, CMT can lead to significant long-term toxicity in a typically young patient population; as a result, there has been a push in the field to develop novel treatment strategies that can maintain robust patient survival while minimizing the risk of treatment-related complications. This has been primarily explored by 2 mechanisms: first, the use of response-adapted treatments based on interim FDG-PET\/CT; and second, the incorporation of novel therapies, including the CD30-directed antibody-drug conjugate brentuximab vedotin (BV) and immune checkpoint blockade. In this article, we provide a historical review of the management of early-stage HL and discuss ongoing studies that may change the standard of care for this disease.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000824","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:10Z","timestamp":1779386410000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Early-Stage Hodgkin Lymphoma"],"prefix":"10.1097","volume":"32","author":[{"given":"Kishan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R1-20260521","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1200\/JCO.2001.19.11.2905","article-title":"Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin\u2019s disease: long-term results of a randomized trial of radiotherapy alone","volume":"19","author":"Duhmke","year":"2001","journal-title":"J Clin Oncol"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"key":"R5-20260521","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Brockelmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"R6-20260521","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0360-3016(85)90358-X","article-title":"A multivariate analysis of prognostic factors in early stage Hodgkin\u2019s disease","volume":"11","author":"Tubiana","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20260521","first-page":"1801","article-title":"Prognostic factors in 454 cases of Hodgkin\u2019s disease","volume":"31","author":"Tubiana","year":"1971","journal-title":"Cancer Res"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol"},{"key":"R10-20260521","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"EVIDoa2500115","DOI":"10.1056\/EVIDoa2500115","article-title":"An individualized prediction model for early-stage classic Hodgkin\u2019s lymphoma","volume":"4","author":"Rodday","year":"2025","journal-title":"NEJM Evid"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/annonc\/mdi200","article-title":"Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma","volume":"16","author":"Hutchings","year":"2005","journal-title":"Ann Oncol"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"R15-20260521","first-page":"475","article-title":"The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin\u2019s disease","volume":"91","author":"Gallamini","year":"2006","journal-title":"Haematologica"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"17702","DOI":"10.1038\/s41598-022-22032-3","article-title":"Interim FDG-PET\/CT for therapy monitoring and prognostication in Hodgkin\u2019s lymphoma","volume":"12","author":"Al-Ibraheem","year":"2022","journal-title":"Sci Rep"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","article-title":"Early interim 18F-FDG PET in Hodgkin\u2019s lymphoma: evaluation on 304 patients","volume":"39","author":"Zinzani","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/10428194.2011.603444","article-title":"Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone","volume":"53","author":"Markova","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R21-20260521","first-page":"CD012643","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","volume":"1","author":"Aldin","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1182\/blood.2023020326","article-title":"The next frontier: enter PD-1 and exit PET scans?","volume":"141","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1148\/96.3.603","article-title":"Preliminary experience with total nodal irradiation in Hodgkin\u2019s disease","volume":"96","author":"Johnson","year":"1970","journal-title":"Radiology"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.1998.16.3.830","article-title":"Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin\u2019s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin\u2019s Disease Collaborative Group","volume":"16","author":"Specht","year":"1998","journal-title":"J Clin Oncol"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N Engl J Med"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2017.10.015","article-title":"Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F intergroup randomized trial","volume":"100","author":"Thomas","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized Hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J Clin Oncol"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"R36-20260521","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1200\/jco.2005.23.16_suppl.6505","article-title":"First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin\u2019s lymphoma (HL)","volume":"23","author":"Noordijk","year":"2005","journal-title":"J Clin Oncol"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"R38-20260521","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"R39-20260521","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/blood-2024-200719","article-title":"Pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin (P-GVD) for classical Hodgkin lymphoma (CHL) in the real-world setting","volume":"144","author":"Baek","year":"2024","journal-title":"Blood"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1080\/10428194.2022.2107204","article-title":"Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory\/relapsed Hodgkin lymphoma: a lymphoma study association phase I\/II study","volume":"63","author":"Stamatoullas","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/01.HS9.0000890668.27643.97","article-title":"P025: RADAR: an international phase III, PET response-adapted, randomised trial in progress, comparing ABVD\u00b1ISRT with brentuximab vedotin+AVD\u00b1ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma","volume":"6","author":"Radford","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"R44-20260521","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1182\/blood-2023-189652","article-title":"AHOD2131: a randomized phase 3 response-adapted trial comparing standard therapy with immuno-oncology therapy for children and adults with newly diagnosed stage I and II classic Hodgkin lymphoma","volume":"142","author":"Henderson","year":"2023","journal-title":"Blood"},{"key":"R45-20260521","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.005","article-title":"ABVD or BEACOPP(baseline) along with involved-field radiotherapy in early-stage Hodgkin lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) H9-U intergroup randomised trial","volume":"81","author":"Ferme","year":"2017","journal-title":"Eur J Cancer"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"key":"R49-20260521","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"key":"R51-20260521","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"R52-20260521","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.22.00947","article-title":"Positron emission tomography-adapted therapy in bulky stage I\/II classic Hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce","year":"2023","journal-title":"J Clin Oncol"},{"key":"R53-20260521","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"key":"R54-20260521","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"R55-20260521","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"R56-20260521","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"suppl 16","key":"R57-20260521","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1200\/JCO.2025.43.16_suppl.7040","article-title":"Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab","volume":"43","author":"Lynch","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:17Z","timestamp":1779386417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000824","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-10-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}